Diagnostic methods

Abstract

The present disclosure relates to diagnostic tests for the early detection of pancreatic cancer (i.e., pancreatic ductal adenocarcinoma (PDAC)) or pancreatitis in cohorts of patients selected for an increased risk of PDAC associated with diabetes mellitus (DM), including therapeutic regimens for the treatment of subjects with PDAC and kits for use in the methods of the invention.

Description

[Technical field]

[0001] The present disclosure relates to diagnostic tests for the early detection of pancreatic cancer (i.e., pancreatic ductal adenocarcinoma (PDAC)] or pancreatitis in patient cohorts selected for their increased risk of developing PDAC associated with diabetes mellitus (DM). [Background technology]

[0002] The transformation of normal cells into cancer cells often involves successive somatic and / or genetic mutations in the DNA sequence of several genes, resulting in functional changes in cellular proteins that confer a growth advantage, and in changes in the expression levels (mRNA and protein levels) of additional genes that are not themselves mutated but that contribute to the growth advantage of the cancer cells. Gene mutations inherited in the germline (from one or both parents) may also predispose individuals to the development of cancer. However, cancer in general, and pancreatic ductal adenocarcinoma (PDAC) in particular, are largely not "genetically determined" in the classical sense.

[0003] The pancreas has a complex anatomical and cellular organization, including endocrine cells that release several important hormones (such as insulin, glucagon, and somatostatin) into the blood, and exocrine cells that secrete lipases and proteases into the intestine to aid in digestion. It is the exocrine pancreas that is believed to be the tissue of origin for PDAC. PDAC typically has vague symptoms or is considered asymptomatic until late stages, often allowing metastasis to other organs before being diagnosed. The median survival time for untreated metastatic PDAC is 3-5 months. The survival time for locally advanced disease is 6-10 months. However, the majority of cases are diagnosed at an advanced stage, too late for potentially curative resection. Moreover, chemotherapy is not curative, thereby causing PDAC mortality to approach incidence.

[0004] During the asymptomatic period leading up to clinical diagnosis, the primary tumor releases potentially metastatic "seed" cells into the circulation. If resection is performed when the tumor is less than 1 cm, the 5-year survival rate is much better than when the tumor is larger (75% compared with approximately 5%). If all patients could be diagnosed when their tumors were less than 1 cm, surgical resection could dramatically improve survival. However, there are currently no reliable means of detecting asymptomatic PDAC.

[0005] The incidence of PDAC is increasing and is predicted to surpass breast cancer as the second leading cause of cancer-related death by 2030. Because PDAC is typically detected at an advanced stage, the majority of PDAC patients are not eligible for potentially curative surgery, but when surgery is possible, overall survival has been shown to be significantly improved.

[0006] There are practical barriers to screening the general public for PDAC. Although the disease is a leading cause of cancer death, it is relatively rare, occurring with an incidence of only 0.014%. Therefore, a screening test would need to be highly specific and approach 100% to avoid a large number of false positives. However, no such screening test currently exists. CA19-9 is the only biomarker in routine clinical use for the management of PDAC. However, its low sensitivity and specificity, the extremely high false positive rate in screening tests, and the cost of follow-up testing to confirm the diagnosis make screening ineffective and expensive.

[0007] Other markers are known in the art. US Patent Publication No. 9,863,960 discloses a method for diagnosing pancreatic cancer by measuring the presence of interleukin-1 receptor antagonist (IL-1Ra). International Patent Publication No. 2017109518 discloses a method for determining the protein glycosylation signature of a target protein to determine whether a subject is suffering from pancreatic cancer. Hyperglycosylation of CA-19-9 and CEA has been shown to be associated with pancreatic cancer. Furthermore, US Patent Publication No. 20170003294 and International Patent Publication No. 2015157557 disclose diagnostic tests for detecting diseases such as pancreatic cancer or pancreatic inflammatory conditions, including determining the presence or absence of a range of biomarkers.

[0008] Studies have shown that the majority of PDAC patients have diabetes mellitus (DM) at the time of PDAC diagnosis 1、2 In contrast, the prevalence of DM in individuals with lung, breast, prostate, and colorectal cancer is not higher than in non-cancer controls. 3 The relationship between PDAC and DM is complex. Long-standing DM increases the risk of PDAC, but only by about twofold (roughly equivalent to smoking). However, epidemiological data indicate that PDAC can cause DM and that new-onset DM is an early warning sign of the presence of PDAC. 4 In approximately 50% of PDAC cases, diabetes is recent in onset (within 3 years), making individuals with new-onset DM the highest risk group for PDAC. The median time between diagnosis of new-onset DM and subsequent diagnosis of PDAC is 13 months.

[0009] This represents a substantial opportunity for earlier detection of PDAC, but there are challenges. The incidence of DM in the general population is rising, with an estimated 200,000 new cases of type 2 DM (T2DM) diagnosed each year in the UK. In 10% of new-onset DM cases, DM is secondary to pancreatic disease (PDAC, chronic pancreatitis, etc.), known as type 3cDM, but most often misdiagnosed as T2DM. 5 .

[0010] The present disclosure relates to the characterization of a highly specific test for the detection of PDAC or pancreatitis in individuals with new-onset diabetes, which measures levels of adiponectin and IL-1Ra in biological samples and distinguishes exocrine pancreatic diabetes (type 3c, including PDAC and parapancreatitis-associated DM) from T2DM, allowing the former to participate in screening for PDAC. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] U.S. Patent No. 9,863,960 [Patent Document 2] International Patent Publication No. 2017109518 [Patent Document 3] U.S. Patent Publication No. 20170003294 [Patent Document 4] International Patent Publication No. 2015157557 Summary of the Invention

[0012] According to one aspect of the invention there is provided an immunoassay for determining whether a subject has elevated levels of adiponectin polypeptide and IL-1Ra polypeptide, comprising: i) obtaining a biological sample from a subject; ii) forming a preparation comprising the sample, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; iii) detecting each complex; and iv) comparing the levels of adiponectin and IL-1Ra with relevant matched controls.

[0013] The present disclosure compares samples obtained from test subjects to relevant matched controls, which can be, for example, subjects suffering from or suspected of having new-onset DM without concomitant pancreatic cancer.

[0014] According to one aspect of the present invention, there is provided an immunoassay for determining whether a subject is suspected of having early stage pancreatic ductal adenocarcinoma or pancreatitis, comprising: i) obtaining a biological sample from a subject; ii) forming a preparation comprising the sample, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; iii) detecting each complex; iv) comparing the levels of adiponectin and IL-1Ra polypeptides with relevant matched controls.

[0015] Pancreatitis is an inflammation of the pancreas and can be acute or chronic. In acute pancreatitis, the pancreas is only inflamed for a short period of time and there is often no lasting damage. In chronic pancreatitis, the pancreas is permanently damaged and either cannot produce any digestive juices or cannot produce sufficient amounts of digestive juices. The symptoms of chronic pancreatitis are often very similar to pancreatic cancer.

[0016] In a preferred method of the invention, said pancreatitis is acute or chronic pancreatitis, preferably chronic pancreatitis.

[0017] In a preferred method of the invention, the adiponectin polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or a polymorphic sequence variant thereof.

[0018] In a preferred method of the invention, the level of adiponectin polypeptide is increased at least 2-fold compared to the normal matched control.

[0019] In a preferred method of the invention, the IL-1Ra polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2 or a polymorphic sequence variant thereof.

[0020] In a preferred method of the invention, the level of IL-1Ra polypeptide is increased at least 2-fold compared to the normal matched control.

[0021] In a preferred method of the invention, the subject undergoes pre-screening to determine whether the subject is pre-diabetic or suffers from early stage T2DM.

[0022] Symptoms of diabetes can vary but include excessive thirst, frequent urination, fatigue, weight and muscle loss, frequent bouts of thrush, slow-healing cuts or wounds, and blurred vision.Diabetes is usually diagnosed by measuring the level of glucose in the blood.

[0023] In a preferred method of the invention, the subject is tested for diabetes.

[0024] In a preferred method of the invention, the level of CA19-9 is determined as a measure of whether a subject has or is susceptible to PDAC.

[0025] In an alternative method of the invention, the level of CA19-9 is determined as a measure of whether a subject is suffering from or susceptible to suffering from pancreatitis.

[0026] In a preferred method of the invention, said pancreatitis is acute or chronic pancreatitis, preferably chronic pancreatitis.

[0027] Many monoclonal antibodies have been developed against the CA19-9 antigen, a carbohydrate structure called sialyl Lewis A (part of the Lewis family of blood group antigens) that has the sequence Neu5Acα2,3Galβ1,3(Fucα1,4)GlcNAc. Sialyl Lewis A is synthesized by glycosyltransferases that sequentially link monosaccharide precursors to both N-linked and O-linked glycans.

[0028] In a preferred method of the invention, CA19-9 levels are determined by immunoassay.

[0029] In a preferred method of the invention, the immunoassay is an ELISA or a bead-based immunoassay.

[0030] Alternative formats of the immunoassays of the present disclosure may be used, such as sandwich assays, Western blots, mass spectrometry-based detection, ELISA, or bead-based immunoassays such as Luminex®, however, the practice of the present invention is not limited to any particular immunoassay format and other formats available to one of skill in the art may be used.

[0031] In a preferred method of the invention, the biological sample is selected from the group consisting of urine, blood, plasma, or serum.

[0032] Urine is an important source of biomarkers and can be collected continuously in a non-invasive manner and is preferable to regular blood sampling. Detection of IL-1Ra in urine is a standard procedure (21), and commercial kits for detection of IL-1Ra in urine are widely available (Table 1). Adiponectin can be detected in urine from healthy subjects using commercial kits such as the Luminex assay kit.

[0033] In a preferred method of the invention, the biological sample is urine.

[0034] In a preferred method of the invention, the antibody is a polyclonal serum.

[0035] In an alternative method of the invention, the antibody is a monoclonal antibody.

[0036] In a preferred method of the invention, the subject is imaged, for example by tomography or magnetic resonance imaging, to determine whether the subject is afflicted with early stage pancreatic ductal adenocarcinoma or pancreatitis.

[0037] According to a further aspect of the present invention, there is provided a treatment regimen for early stage pancreatic ductal adenocarcinoma or pancreatitis, comprising: i) carrying out a method according to the invention on a subject suspected of having early stage pancreatic ductal adenocarcinoma or pancreatitis; ii) treating the subject for early stage pancreatic ductal adenocarcinoma or pancreatitis if the subject is determined by the method to be suffering from or susceptible to early stage pancreatic ductal adenocarcinoma or pancreatitis.

[0038] In a preferred embodiment of the invention, the treatment is resection of tumor tissue.

[0039] In an alternative embodiment of the invention, the treatment is the administration of one or more chemotherapeutic agents.

[0040] In a preferred embodiment of the invention, the therapeutic agent is selected from the group consisting of FOLFIRINOX (oxaliplatin, leucovirin, irinotecan, and fluorouracil), gemcitabine, GemCap (gemcitabine and capecitabine), FOLFOX (oxaliplatin, fluorouracil and folinic acid), and Nab-paclitaxel gemcitabine.

[0041] According to a further aspect of the present invention there is provided a solid support comprising an immobilized antibody that specifically binds adiponectin and / or IL-1Ra.

[0042] In a preferred embodiment of the invention, the solid support further comprises an immobilized antibody that specifically binds to CA19-9.

[0043] The antibodies that specifically bind to adiponectin, IL-1Ra, and CA19-9 are preferably monoclonal antibodies.

[0044] According to a further aspect of the invention there is provided a point-of-care device comprising a solid support according to the invention.

[0045] According to a further aspect of the present invention, An antibody that specifically binds to an adiponectin polypeptide; an antibody that specifically binds to an IL-1Ra polypeptide; Kits are provided that comprise or consist of a second antibody that binds to the monoclonal antibody that binds to an adiponectin polypeptide, and a second antibody that binds to an IL-1Ra polypeptide, where the second antibody comprises or is a separate detectable label.

[0046] In a preferred embodiment of the present invention, there is provided an antibody that binds to CA-19 and a secondary antibody that binds to CA19-9 that includes a separately detectable label.

[0047] The antibodies that specifically bind to adiponectin, IL-1Ra, and CA19-9 are preferably monoclonal antibodies.

[0048] According to a further aspect of the present invention, there is provided a method for determining whether a subject should be imaged for early stage pancreatic ductal adenocarcinoma or pancreatitis, comprising: i) obtaining a biological sample from a subject; ii) forming a preparation comprising the sample, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; iii) detecting each complex; iv) comparing the levels of adiponectin polypeptide and IL-1Ra polypeptide with relevant matched controls; v) determining whether the subject should be imaged to determine whether the subject is suffering from early stage pancreatic ductal adenocarcinoma or pancreatitis.

[0049] In a preferred method of the invention, the subject is imaged, for example by tomography or magnetic resonance imaging, to determine whether the subject is afflicted with early stage pancreatic ductal adenocarcinoma or pancreatitis.

[0050] Throughout the description and claims of this specification, the words "comprise" and "contain," as well as variations of words such as "comprising" and "comprises," mean "including, but not limited to," and do not intend (and do not exclude) the exclusion of other parts, addenda, components, wholes, or steps. "Consisting essentially of" means including wholes having essential wholes, but which do not substantially affect the function of the essential wholes.

[0051] Throughout the description and claims of this specification, the singular encompasses the plural unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood as contemplating singularity as well as plurality, unless the context requires otherwise.

[0052] It is to be understood that any feature, integer, property, compound, chemical moiety, or group described in connection with a particular aspect, embodiment, or example of the invention is applicable to any other aspect, embodiment, or example described herein, unless incompatible therewith.

[0053] Embodiments of the invention will now be described, by way of example only, with reference to the following figures: [Brief description of the drawings]

[0054] [Figure 1] Approximately 10% of all individuals newly diagnosed with T2DM actually have T3cDM. PDAC-associated DM accounts for 8-10% of T3cDM. T3cDM; type 3c diabetes, T2DM; type 2 diabetes. [Diagram 2] Serum adiponectin measured in three independent cohorts indicates that levels of this adipokine are higher in PDAC-DM patients compared to DM controls and can distinguish PDAC from long-standing T2DM and new-onset T2DM. PC: pancreatic cancer, PDAC-DM: diabetes associated with pancreatic cancer, DM: long-standing diabetes, NOD: new-onset diabetes, HC: healthy controls. [Diagram 3] Circulating levels of IL-1Ra measured in two independent cohorts. IL-1Ra is upregulated in patients with PDAC and PDAC-DM compared to T2DM patients, regardless of duration (A, B). PDAC: pancreatic cancer, PDAC-DM: diabetes associated with pancreatic cancer, DM: long-standing diabetes, NOD: new-onset diabetes. [Figure 4] Serum levels of adiponectin (A) and plasma levels of IL-1Ra (B) are significantly elevated in T3cDM patients (PDAC-associated and chronic pancreatitis-associated) compared with T2DM patients. T3cDM: type 3c diabetes, T2DM: type 2 diabetes. [Diagram 5] Serum adiponectin and plasma IL-1Ra, in combination, performed better in discriminating between type 3c diabetes and type 2 diabetes, regardless of diabetes duration (A) or compared with new onset alone (B) (T3cDM: type 3c diabetes, T2DM: type 2 diabetes, NOD: new onset diabetes). [Figure 6]Biomarker-mediated identification of PDAC (black individuals) among individuals with new-onset DM (all colors) and a pathway to diagnosis. Differentiating T3cDM (dark gray and black individuals) from T2DM (gray individuals) identifies a population rich in PDAC and makes screening of this subpopulation feasible. All T3cDM patients require management different from that typically presented to T2DM patients. Our focus is on the detection of PDAC. PDAC accounts for 10% of cases in the T3cDM group. [Figure 7] Calibration curve obtained from plate 1 of the Luminex assay showing the adiponectin concentration (pg / mL) measured in each standard and sample versus fluorescence intensity. The optimal urine dilution was placed on the linear section of the curve between S2 and S4 (circled in red). [Figure 8] Calibration curve obtained from plate 2 of the Luminex assay showing the adiponectin concentration (pg / mL) measured in each standard and sample versus fluorescence intensity. The optimal urine dilution was placed on the linear section of the curve between S2 and S4 (circled in red). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055] material and method patient group Serum and plasma samples from individuals with pancreatic cancer (pre-surgery) and healthy subjects were obtained from the University of Liverpool GCP Research Facility Biobank. Serum and plasma samples from individuals with diabetes were collected at the Royal Liverpool University Hospital after referral from the Diabetes Clinic and Primary Care Center. All participants gave written informed consent using an approved ethical protocol at the Royal Liverpool University Hospital (Ethics IDs: 11 / NW / 0083 and 16 / LO / 1630).

[0056] Sample cohort Three independent sets of samples were analyzed. The first discovery set (n=60) consisted of 40 individuals with histologically confirmed PDAC and 20 healthy control individuals. Individuals with PDAC were further subclassified into those with a positive diagnosis of diabetes (12 patients, HbA1c ≥ 48 mmol / mol) and those with a negative or undefined diagnosis of diabetes (28 patients, HbA1c < 47 mmol / mol or no data). To determine the levels of candidate markers in individuals with type 2 diabetes, a second independent training sample set (n=135) was analyzed. This included 80 individuals with histologically confirmed PDAC (40 diagnosed with diabetes and 40 diagnosed with diabetes negative), 20 individuals with chronic pancreatitis (10 diagnosed with diabetes and 10 diagnosed with diabetes negative), 20 individuals with long-term (> 3 years after diagnosis) type 2 diabetes, and 15 controls. A third independent validation set (n=175) was used to evaluate the levels of candidate markers in individuals with new-onset type 2 diabetes (diagnosed less than 3 years) consisting of 78 individuals with histologically confirmed PDAC (37 diagnosed with diabetes and 41 diagnosed with diabetes negative), 39 individuals with chronic pancreatitis (19 diagnosed with diabetes and 20 diagnosed with diabetes negative), 20 individuals with long-standing type 2 diabetes (>3 years after diagnosis), 18 individuals with new-onset type 2 diabetes (diagnosed less than 3 years), and 20 healthy subjects.

[0057] Individuals with PDAC had resectable disease and underwent surgery with curative intent.

[0058] Sampling Blood was collected into Sarstedt Monovette Serum Z tubes or K+EDTA tubes (Sarstedt Ltd, Leicester, UK) and left at room temperature for 30 min before centrifugation at 800×g for 10 min for serum fraction and 16000×g for 1 min for plasma fraction. Serum and plasma fractions were aliquoted into cryotubes and stored at −80° C. before use.

[0059] Discovery Analysis Luminex and mass spectrometry-based isobaric tags for relative and absolute quantification (iTRAQ) were performed using a discovery subset of samples, PDAC (n=40) and healthy controls (n=20, total n=60), as previously described ADDIN EN.CITE ADDIN EN.CITE.DATA 6、7 The list of significantly altered proteins generated from our iTRAQ data was uploaded into Ingenuity Pathway Analysis (IPA) software (http: / / www.ingenuity.com). Both core analysis and biomarker filters were performed to identify proteins related to metabolic disease pathways and diabetes.

[0060] training analysis Candidate biomarkers generated via IPA were evaluated using immunoassays in 135 serum and plasma samples; PDAC (n=40 with diabetes, n=40 without diabetes), chronic pancreatitis (n=10 with diabetes, n=10 without diabetes), long-standing type 2 diabetes (n=20), and healthy controls (n=20).

[0061] Verification Analysis Immunoassays were used to evaluate the most promising markers that emerged from the training analysis in 175 serum and plasma samples; PDAC (n=37 with diabetes, n=41 without diabetes), chronic pancreatitis (n=19 with diabetes, n=20 without diabetes), long-standing type 2 diabetes (n=20), new-onset type 2 diabetes (n=18), and healthy controls (n=20).

[0062] Biomarker Measurement and Data Filtering Serum adiponectin and plasma IL-1Ra levels were measured using commercial Luminex assays (Bio-Plex Pro Diabetic Adiponectin Assay and Bio-Plex Pro Human Cytokine 27-Plex Assay, respectively, Bio-Rad, UK) on a Bio-Plex 200 system (Bio-Rad, UK). All samples were measured in duplicate according to the manufacturer's instructions, with interplate variability assessed using three quality controls per plate.

[0063] Biomarker concentrations were determined from standard curves of positive control proteins using a four- or five-parameter logistic regression model. Plate-to-plate variation of 15% or less was considered acceptable, and any plates outside this range were repeated. Quantified biomarkers whose concentrations did not fall within the linear range and those with duplicate measurements with a coefficient of variation (CV) greater than 20% were removed from the dataset.

[0064] Blood glucose levels (HbA1c mmol / mol) were measured by the Department of Clinical Biochemistry at the Royal Liverpool University Hospital using an International Union of Clinical Chemistry approved method.

[0065] statistical analysis JMP version 14 (SAS Institute Inc., Cary, NC, USA) and RStudio version 1.1.463 (Integrated Development for R, RStudio Inc., Boston, MA, USA, http: / / rstudio.com / ) were used. Protein expression data were analyzed using a two-tailed Mann-Whitney U test, and stepwise regression models were used to select the most promising marker combinations. The diagnostic accuracy of each candidate marker (adiponectin and IL-1Ra), both alone and in combination, was assessed by ROC analysis.

[0066] Urine sample collection Urine samples were obtained from two healthy subjects and processed with and without protease inhibitors. Urine samples were subjected to the following dilutions: (1:1), (1:2), (1:4), (1:5), (1:10), (1:20), (1:100). Plasma controls were obtained from one healthy subject and one pancreatic cancer patient and prepared to a dilution of (1:400). Adiponectin levels were measured using Bio-Plex Pro Human Diabetes Adiponectin Assay (Bio-Rad, #171A7003M).

[0067] Data was processed using Bio-Plex Manager software. Adiponectin concentrations were averaged and the calculated coefficient of variation (CV) values ​​were less than 15% and were considered acceptable for standards and samples. Data points with CVs greater than 15% were marked as outliers, resulting in the generation of an 8-point calibration curve for further analysis.

[0068] A quality control check was also performed using adiponectin concentrations in plasma controls, where CV values ​​below 15% were considered acceptable. [Table 1]

[0069] Example 1 Distinguishing new-onset DM caused by PDAC from T2DM will allow for earlier diagnosis of PDAC.

[0070] The incidence of DM in the general population is rising, with an estimated 200,000 new cases of type 2 diabetes mellitus (T2DM) diagnosed each year in the UK. In 10% of new-onset DM cases, DM is secondary to pancreatic disease (PDAC, chronic pancreatitis, etc.) and is known as type 3c DM (T3cDM), although the vast majority of cases are misdiagnosed as T2DM (Figure 1). 8 PDAC-associated DM accounts for 8-10% of misdiagnosed new-onset T3cDM cases (corresponding to 0.8-1% of new diagnoses of T2DM).

[0071] Identifying the 0.8-1% of individuals with new-onset diabetes who have underlying PDAC-associated DM is not feasible using current screening modalities. Differentiating T3cDM from T2DM would identify a population with a high prevalence of PDAC, making screening of this subpopulation feasible. Establishment of diagnostic biomarkers would facilitate screening and, in combination with other clinical features, help identify these high-risk individuals.

[0072] Serum and plasma were extensively analyzed for the detection and development of protein biomarkers to improve early diagnosis of PDAC. 6、7、9~15 A comprehensive discovery program was conducted using isobaric tags for relative and absolute quantification (iTRAQ) in combination with liquid chromatography-tandem mass spectrometry (LC-MS / MS) and immunoassays (Luminex, Rules Based Medicine, ELISA, and Western blot).

[0073] Using over 500 diagnostic and control samples obtained from Liverpool, the discovery work identified 379 differentially regulated serum proteins in PDAC. Ingenuity Pathway Analysis (IPA) selected these differentially expressed proteins related to metabolic disease pathways and diabetes. Analysis of a subset of these samples in which DM status was known allowed to observe differences between pancreatic cancer (irrelevant to DM status) and healthy controls. Subsequent analysis of 19 candidate biomarkers using independent serum and plasma training and validation sets highlighted adiponectin and interleukin-1 receptor antagonist (IL-1Ra) as important potential components of a novel panel for the detection of T3cDM, including PDAC-DM.

[0074] Low circulating adiponectin (<4 μg / mL) is associated with T2DM 16However, we observed a significant increase in serum levels of this adipokine in PDAC patients (regardless of DM status) compared to healthy controls in independent discovery, training, and validation sample sets (Figure 2). In our training set, for PDAC and DM patients (n=89), adiponectin was shown to be elevated in both diabetic and nondiabetic PDAC patients compared to long-term DM controls (p=0.001 and p=0.0004, respectively, Figure 2B). Adiponectin levels were similar between patients with chronic pancreatitis and PDAC and were not affected by jaundice (data not shown). This is an important consideration, as we have previously demonstrated the effect of elevated bilirubin on the measured levels of certain proteins in the blood. 12 .

[0075] Validation in an independent cohort (n=175) confirmed that adiponectin levels were significantly elevated in individuals with PDAC compared to those with T2DM. Elevated serum adiponectin was observed regardless of duration of DM (both long-standing and new-onset T2DM) (Figure 2C). Adiponectin was also found to be elevated in diabetic (n=19) and non-diabetic (n=20) chronic pancreatitis (CP) patients compared to T2DM controls (n=39, data not shown).

[0076] In individuals with newly diagnosed DM, there was a significant reduction in adiponectin levels at the time of diagnosis 17 , higher levels of adiponectin may underscore the presence of PDAC. Furthermore, lower circulating levels of adiponectin are predictive for T2DM, increasingly suggesting that adiponectin measurement may provide an early means of identification of impending diabetes. 18 Increased awareness of the role of adiponectin in DM diagnosis provides an opportunity to detect PDAC-associated DM.

[0077] Our data suggest that individuals with clinical indications of DM but normal to high adiponectin should be screened for pancreatic cancer.

[0078] Interleukin-1 receptor antagonists (IL-1Ra) reduce the endogenous activity of the IL-1 family of proinflammatory cytokines and protect β-cells from the destructive effects of high glucose exposure. β-cell expression of IL-1Ra is reduced in patients with T2DM, whereas 19 IL-1Ra expression is not affected by jaundice and was found to be elevated in PDAC compared to healthy controls in both serum and plasma in a Luminex-based discovery program. 20 ). This observation was confirmed in plasma in independent training and validation sets, where levels were shown to be significantly elevated in both PDAC and PDAC-DM compared to T2DM (p<0.006 and <0.03, respectively, Figure 3A and Figure 3B) and new-onset T2DM (p<0.0001, Figure 3B). Our data support the use of circulating IL-1Ra as a valuable marker for earlier detection of PDAC in high-risk individuals with newly diagnosed DM.

[0079] Although circulating concentrations of adiponectin and IL-1Ra were found to be elevated in PDAC regardless of DM status, and also in CP (not shown), a significant separation of median biomarker levels was observed between the two groups (p<0.0001, Figures 4A and 4B), highlighting their potential role as markers for identifying T3cDM (PDAC-associated and CP-associated) in individuals diagnosed with T2DM.

[0080] Increased expression of both adiponectin and IL-1Ra in PDAC and chronic pancreatitis (CP) compared to T2DM controls, regardless of DM status, indicates a type 3c-specific effect (Figure 4). Furthermore, the combination of adiponectin and IL-Ra showed good performance in distinguishing T3cDM (PDAC-associated and CP-associated) from T2DM (AUC 0.90, Figure 5A), with a sensitivity / specificity of 73.7% / 83.7%. More specifically, the combination of adiponectin and IL-1Ra achieved an AUC of 0.91, with a sensitivity and specificity of 83.7% in distinguishing T3cDM from individuals with new-onset T2DM (Figure 5B).

[0081] Our test targets the estimated 200,000 new individuals diagnosed with T2DM each year in the UK. Our marker allows for differentiation of new onset DM caused by common T2DM from new onset DM caused by T3cDM. Identifying individuals with T3cDM (including both PDAC and CP) selects for a subpopulation in which PDAC is highly prevalent (Figure 6). Identifying those at highest risk for a PDAC diagnosis then makes prospective screening (of this subpopulation) feasible using existing modalities (EUS, CT / MRI scans, biochemistry panels) (Figure 6). Our test also selects for patients with CP.

[0082] Example 2 Adiponectin was successfully detected in urine using the Luminex assay (Table 2) and the concentrations are measurable according to the generated calibration curves (Figures 7 and 8). The optimal dilutions of urine were (1:1) and (1:2) as these samples were located between the linear parts of the standard curve. Little difference in adiponectin concentrations was observed for urine treated with and without protease inhibitors. Adiponectin levels are measurable in urine. Urine is therefore suitable for the measurement of adiponectin and IL-1RA. [Table 2]

[0083] References ADDIN EN.REFLIST 1.Permert J,Ihse I,Jorfeldt L,et al.Pancreatic cancer is associated with impaired glucose metabolism.Eur J Surg 1993;159:101-7. 2.Pannala R,Leirness JB,Bamlet WR,et al.Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus.Gastroenterology 2008;134:981-7. 3.Aggarwal G,Kamada P,Chari ST.Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers.Pancreas 2013;42:198-201. 4.Andersen DK,Korc M,Petersen GM,et al.Diabetes,Pancreatogenic Diabetes,and Pancreatic Cancer. Diabetes 2017;66:1103-1110. 5.Sah RP,Nagpal SJ,Mukhopadhyay D,et al.New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013;10:423-33. 6.Jenkinson C,Elliott VL,Evans A,et al.Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.Clin Cancer Res 2016;22:1734-43. 7.Shaw VE,Lane B,Jenkinson C,et al.Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Mol Cancer 2014;13:114. 8.Woodmansey C,McGovern AP,McCullough KA,et al.Incidence, Demographics,and Clinical Characteristics of Diabetes of the Exocrine Pancreas(Type 3c):A Retrospective Cohort Study.Diabetes Care 2017;40:1486-1493. 9.Jenkinson C,Elliott V,Menon U,et al.Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.J Proteomics 2014;113C:400-402. 10.O’Brien DP,Sandanayake NS,Jenkinson C,et al.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer:implications for early disease detection.Clin Cancer Res 2015;21:622-31. 11.Sinclair J,Timms JF.Quantitative profiling of serum samples using TMT protein labelling,fractionation and LC-MS / MS.Methods 2011;54:361-9. 12.Tonack S,Jenkinson C,Cox T,et al.iTRAQ reveals candidate pancreatic cancer serum biomarkers:influence of obstructive jaundice on their performance.Br J Cancer 2013;108:1846-53. 13.Tonack S,Neoptolemos JP,Costello E.Analysis of serum proteins by LC-MS / MS.Methods Mol Biol 2010;658:281-91. 14.Tonack S,Aspinall-O’Dea M,Jenkins RE,et al.A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ.J Proteomics 2009;73:352-6. 15.Yan L,Tonack S,Smith R,et al.Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer.J Proteome Res 2009;8:142-8. 16.Kawada T,Hasegawa M.Predictive ability of serum high-molecular-weight adiponectin in combination with serum insulin and serum C-reactive protein for the presence of metabolic syndrome.Ann Hum Biol 2012;39:108-12. 17.Herder C,Carstensen M,Ouwens DM.Anti-inflammatory cytokines and risk of type 2 diabetes.Diabetes Obesity & Metabolism 2013;15:39-50. 18.Anderson SG,Dunn WB,Banerjee M,et al.Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes.Plos One 2014;9. 19.Marculescu R,Endler G,Schillinger M,et al.Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002;51:3582-5. 20.Shaw VE,Lane B,Jenkinson C,et al.Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Molecular Cancer 2014;13. ADDIN EN.REFLIST 21.Zwiech R.Predictive value of conjointly examined IL-1ra,TNF-R I,TNF-R II,and RANTES in patients with primary glomerulonephritis.J Korean Med Sci.2013;28(2):261-7. ADDIN EN.REFLIST 22.Karpenko MN,Vasilishina AA,Gromova EA,Muruzheva ZM,Miliukhina IV,Bernadotte A.Interleukin-1beta,interleukin-1 receptor antagonist,interleukin-6,interleukin-10,and tumor necrosis factor-alpha levels in CSF and serum in relation to the clinical diversity of Parkinson’s disease.Cell Immunol.2018;327:77-82. 23.Arnalich F,Lopez J,Codoceo R,Jim nez M,Madero R,Montiel C.Relationship of plasma leptin to plasma cytokines and human survivalin sepsis and septic shock.The Journal of infectious diseases.1999;180(3):908-11. 24.Zwiech R.Predictive value of conjointly examined IL-1ra,TNF-R I,TNF-R II,and RANTES in patients with primary glomerulonephritis.J Korean Med Sci.2013;28(2):261-7.

Claims

1. An immunoassay method for testing levels of adiponectin polypeptide and IL-1Ra polypeptide, comprising: i) forming a preparation comprising a plasma or serum sample obtained from a subject, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; ii) detecting the levels of adiponectin and IL-1Ra in each complex; and iii) comparing the levels of adiponectin and IL-1Ra obtained in step ii) with the levels of adiponectin and IL-1Ra in a relevant matched control, said relevant matched control being a subject suffering from or suspected of suffering from new-onset diabetes mellitus (DM) without either concomitant pancreatic cancer or concomitant pancreatitis.

2. 1. An immunoassay method for testing whether a subject is suspected of having early stage pancreatic ductal adenocarcinoma (PDAC) or pancreatitis, comprising: i) forming a preparation comprising a plasma or serum sample obtained from a subject, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; ii) detecting the levels of adiponectin and IL-1Ra in each complex; and iii) comparing the levels of adiponectin polypeptide and IL-1Ra polypeptide obtained in step ii) with the levels of adiponectin polypeptide and IL-1Ra polypeptide in a relevant matched control, wherein the relevant matched control is a subject suffering from or suspected of suffering from new-onset diabetes mellitus (DM) without either concomitant pancreatic cancer or concomitant pancreatitis.

3. The method described in claim 1 or 2, wherein the concomitant pancreatitis is acute pancreatitis or chronic pancreatitis.

4. The method of any one of claims 1 to 3, wherein the adiponectin polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or a polymorphic sequence variant thereof.

5. The method of any one of claims 1 to 3, wherein the IL-1Ra polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2 or a polymorphic sequence variant thereof.

6. The method of any one of claims 1 to 5, further comprising detecting the level of CA19-9 for use as information regarding whether the subject has or is susceptible to PDAC.

7. The method of claim 6, wherein the level of CA19-9 is detected by immunoassay.

8. The method of any one of claims 1 to 6, wherein the immunoassay is an ELISA or a bead-based immunoassay.

9. The method of any one of claims 1 to 8, wherein the antibody that binds to adiponectin and IL-1Ra is a monoclonal antibody.

10. A solid support for use in the method according to any one of claims 1 to 9, comprising an immobilized antibody that specifically binds to adiponectin and IL-1Ra.

11. The solid support of claim 10, wherein the solid support further comprises an immobilized antibody that specifically binds to CA19-9.

12. The solid support of claim 11, wherein the antibody that specifically binds to adiponectin, IL-1Ra, and CA19-9 is a monoclonal antibody.

13. A point-of-care device comprising a solid carrier described in any one of claims 10 to 12.

14. A kit for use in the method according to any one of claims 1 to 9, comprising: An antibody that specifically binds to an adiponectin polypeptide; an antibody that specifically binds to an IL-1Ra polypeptide; A kit comprising or consisting of a secondary antibody that binds to the antibody that binds to an adiponectin polypeptide, and a secondary antibody that binds to the antibody that binds to an IL-1Ra polypeptide, wherein the secondary antibody comprises a separate detectable label.

15. The kit of claim 14, further comprising an antibody that binds to CA19-9.

16. 1. An immunoassay method for testing whether a subject should be imaged for early stage pancreatic ductal adenocarcinoma or pancreatitis, comprising: i) forming a preparation comprising a plasma or serum sample obtained from a subject, an antibody or antibodies that bind adiponectin, and an antibody or antibodies that bind IL-1Ra to form antibody / adiponectin polypeptide complexes and antibody / IL-1Ra polypeptide complexes; ii) detecting the levels of adiponectin and IL-1Ra in each complex; and iii) comparing the levels of adiponectin polypeptide and IL-1Ra polypeptide obtained in step ii) with the levels of adiponectin polypeptide and IL-1Ra polypeptide in a relevant matched control, wherein the relevant matched control is a subject suffering from or suspected of suffering from new-onset diabetes mellitus (DM) without either concomitant pancreatic cancer or concomitant pancreatitis.

17. 17. The method of claim 16, wherein the associated pancreatitis is acute or chronic pancreatitis.

Images